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Endothelial dysfunction, a term used to describe both the physical damage and
dysregulated physiology of this endothelial lining, is an increasingly recognized
pathophysiological state shared by many cardiovascular diseases. Historically,
the role of endothelial dysfunction in atrial fibrillation (AF) was thought to be
limited to mediating atrial thromboembolism. However, there is emerging
evidence that endothelial dysfunction both promotes and maintains atrial
arrhythmic substrate, predicts adverse outcomes, and identifies patients at high
risk of recurrence following cardioversion and ablation therapy. Treatments
targeted at improving endothelial function also represent a promising new
therapeutic paradigm in AF. This review summarizes the current understanding
of endothelial function in AF.
K E YWORD S
arrhythmia, atrial fibrillation, catheter ablation, endothelial function
1 | INTRODUCTION
The endothelium consists of a single layer of squamous cells which
lines both the peripheral vasculature and the endocardial surface of
the heart. Far from being an inert lining, the endothelium is a complex
endocrine organ with critical roles in regulating vascular tone, he-
mostasis, and inflammation.1 It releases vasoactive mediators in re-
sponse to hemodynamic shear stress, constitutively inhibits the
coagulation cascade to prevent intravascular thrombosis, and actively
recruits immune cells to sites of tissue injury by altering the ex-
pression of adhesion molecules.2 Endothelial dysfunction, a term
used to describe both the physical damage and dysregulated phy-
siology of this endothelial lining, has been implicated in many disease
states including atherosclerosis, diabetes, hypertension, and obesity.3
Over the last 20 years, there has been significant progress in
understanding the role of endothelial dysfunction in atrial fibrillation
(AF). There is now an emerging role for endothelial dysfunction in
promoting and maintaining atrial arrhythmic substrate, inducing atrial
thromboembolism, and predicting AF recurrence following cardio-
version and ablation therapy. This review will summarize the litera-
ture to date and highlight areas for future research.
2 | IS THERE ENDOTHELIAL
DYSFUNCTION IN AF?
Three key modalities have been used to assess endothelial function in
AF: circulating markers of endothelial dysfunction (Figure 1), micro-
scopic visualization of endothelial structure (Figure 2), and physio-
logical measurements of blood flow (Figure 3).
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F IGURE 1 Circulating markers of endothelial dysfunction. 1) Multimeric VonWillebrand factor (VWF) is synthesized within endothelial cells
and secreted by the fusion of Weibel–Palade bodies to the cell membrane. Multimeric VWF is cleaved by the enzyme ADAMTS13 into its active
form. Exposure of VWF to subendothelial collagen stimulates platelet activation and aggregation. 2) Inactive endothelial nitric oxide synthase
(eNOS) is bound to caveolin on the cell membrane. Increased intracellular calcium levels and shear stress increase Ca2+/calmodulin‐dependent
(CaM) kinase and protein kinase A (PKA) phosphorylation of eNOS into its active form. Active eNOS catalyzes the conversion of L‐arginine into
L‐citrulline and nitric oxide (NO). Asymmetric dimethylarginine (ADMA), a methylated analog of L‐arginine, acts as a competitive inhibitor of
eNOS. 3) Adhesion molecules on the cell surface, including E‐selectin, P‐selectin, intercellular adhesion molecule 1 (ICAM‐1), and vascular cell
adhesion molecule‐1 (VCAM‐1), mediate leukocyte adhesion and recruitment. 4) Circulating microparticles, formed from outpouchings of the
endothelial cell membrane, act as vasoactive and procoagulant mediators. They contain phospholipids, enzymes, messenger RNA, and
membrane‐bound adhesion molecules
F IGURE 2 Atrial endocardial changes in atrial fibrillation (AF). (A) Masson trichrome stain of human left atrial tissue. Histological changes
include endocardial thickening (red arrow) and subendothelial fibrosis and immune cell infiltration (yellow arrow). From Sonada et al.4 with
permission. (B) Scanning electron microscopy of left atrial endocardial surface in non‐AF patients. Described as “flat and continuous paving‐
stone‐like arrangement of endothelial cells.” From Masawa et al.5 with permission. (C) Scanning electron microscopy of left atrial endocardial
surface in AF patient. The irregular arrangement of endothelial cells with areas of denudation and microthrombi formation. From Masawa
et al.5 with permission
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Circulating markers of endothelial dysfunction include Von
Willebrand factor (VWF), nitric oxide (NO), asymmetric dimethy-
larginine (ADMA), adhesion molecules, and circulating microparticles.
VWF is a glycoprotein synthesized and released both by endothelial
cells and megakaryocytes (Figure 1). It plays an important role in
platelet adhesion and hemostasis following endothelial injury and,
therefore, raised plasma levels are a widely used measure of en-
dothelial dysfunction.10 Studies have shown that VWF levels are
higher in patients with AF compared to sinus rhythm.11–14 Although
raised VWF levels are raised in many disease states which frequently
co‐exist with AF (hypertension, hyperlipidemia, obesity), AF is asso-
ciated with raised VWF levels after correction for these con-
founders13 and when these confounders are absent.15 VWF levels
have been shown to have a positive correlation with AF burden.
Scridon et al.16 measured plasma levels of VWF from the left atrium,
coronary sinus, and periphery in patients with paroxysmal and per-
manent AF and compared these to sinus rhythm control with
Wolff–Parkinson–White syndrome. They showed that VWF levels
were significantly increased in patients with persistent AF compared
to controls. Patients with paroxysmal AF had raised VWF levels in the
left atrium (but not coronary sinus or periphery), while patients with
persistent AF had raised VWF levels in all three sites. The authors
hypothesize that endothelial dysfunction may be limited to the left
atrium in paroxysmal AF and become more widespread as the AF
burden increases. This is supported by the observation that VWF
levels are positively correlated with the degree of left atrial en-
docardial damage in patients with AF and mitral valve disease.17 In
patients with AF, raised VWF levels have also been shown to be a
predictor of major adverse cardiovascular events (MACEs) and all‐
cause mortality18 but not stroke.19,20
Additional circulating markers of endothelial dysfunction include
molecules involved in NO metabolism. NO is a vasotransmitter syn-
thesized by nitric oxide synthase (NOS), an enzyme that exists in
three isomeric forms (endothelial NOS [eNOS], neuronal NOS, and
inducible NOS). Endothelial cells constitutively express eNOS whilst
cardiomyocytes express all three forms21 (Figure 1). NO plays a cri-
tical role in regulating vascular tone and the antithrombotic proper-
ties of the endothelium, hence reduced NOS expression and low NO
levels are widely used measures of endothelial dysfunction.21 Cai
et al.22 demonstrated that left atrial NO production and left atrial
eNOS expression were significantly reduced in a pig model of
AF. Plasma levels of nitrite/nitrate (plasma NOx), a surrogate for NO
F IGURE 3 Endothelial function assessment by physiological measurement of blood flow. (A) Brachial flow‐mediated dilatation (FMD)
measures the increase in brachial artery diameter following forearm pressure cuff inflation. From Ghiadoni et al.6 with permission. (B) Reactive
hyperemia peripheral arterial tonometry measures the increase in fingertip pulse amplitude following brachial pressure cuff inflation. From
Rosenberry and Nelson7 with permission. (C) Brachial FMD quartile predicts incident atrial fibrillation (AF) in the Framingham heart study. From
Shaikh et al.8 with permission. (D) 15O‐H2O positron emission tomography imaging of adenosine (ADO)‐induced coronary flow reserve (CFR) and
myocardial blood flow (MBF). AF patients have reduced adenosine‐induced coronary flow reserve and myocardial blood flow compared to
matched and young controls. From Range et al.9 with permission
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levels, are reduced in patients with AF compared to sinus
rhythm.23,24 Although most studies support the view that eNOS
expression and NO levels are reduced in AF, the 786T/C poly-
morphism in the promoter of the eNOS gene, associated with re-
duced eNOS expression, is protective for developing new‐onset AF in
Caucasians.25 ADMA, a methylated analog of L‐arginine, is the pre-
cursor of NO.26 It competitively inhibits NOS, and, therefore, raised
ADMA levels are a commonly used marker of endothelial dysfunc-
tion. Several studies have shown that AF is associated with raised
ADMA levels27–30 and that raised ADMA levels predict AF recur-
rence following cardioversion31 and catheter ablation.32 In addition,
raised ADMA levels positively correlate with the CHA2DS2‐VASc
score29,33 and are strongly associated with increased mortality and
stroke in patients with AF.33 One notable exception is data from the
Framingham heart study which showed that the association between
ADMA levels and new‐onset AF became nonsignificant after cor-
rection for confounding cardiovascular risk factors.34
Adhesion molecules are expressed on the endothelial surface and
mediate leukocyte recruitment as part of the inflammatory re-
sponse35 (Figure 1). Increased circulating levels of adhesion mole-
cules are used as markers of endothelial dysfunction but studies
examining their relationship to AF have been divergent. Some studies
have shown raised levels of E‐selectin36,37 and vascular cell adhesion
molecule‐138 in patients with AF. In contrast, Schnabel et al.39 re-
ported no relationship between levels of adhesion molecules and
new‐onset AF. Circulating microparticles are small membrane‐bound
vesicles containing glycoproteins, phospholipids, and other cyto-
plasmic molecules (Figure 1). They are released by endothelial cells
and platelets in response to apoptosis and cellular activation and
have been shown to play an important role as vasoactive mediators
and procoagulants.40 Several studies have shown raised levels of
circulating microparticles in AF41,42 and this has been suggested to be
a further marker of endothelial dysfunction.
While circulating markers support the view that there is sig-
nificant endothelial dysfunction in AF, they do not clearly identify
whether this dysfunction is localized to the atrial endocardium or
alternatively represents more widespread endothelial involvement.
Histological studies on human left atrial tissue have shown wrinkled
endothelial lining and a thickened subendothelial layer with inter-
stitial fibrosis and immune cell infiltration4,5 (Figure 2A). Electron
microscopy of left atrial appendage tissue from patients with AF
showed areas of endothelial desquamation and subendothelial ede-
ma43 (Figures 2B,C). Interestingly, Kume et al.44 noted that in a rat
hypertension model, atrial endothelial changes occurred only 3 days
after abdominal aortic constriction and this was associated with a
significant increase in AF susceptibility.
Physiological measurements of blood flow suggest that en-
dothelial dysfunction in AF not only occurs in the atrial endocardium
but also in the peripheral circulation. Brachial flow‐mediated dilata-
tion (FMD) is an extensively used measure of endothelial function45
(Figure 3A). In brief, an ultrasound probe is used to measure brachial
artery diameter while simultaneously inflating a forearm cuff to in-
duce downstream tissue ischemia and vasodilation. After 5 min, the
cuff is deflated and the subsequent proportionate increase in brachial
artery diameter is measured as a marker of endothelial‐dependent
vasodilation (Figure 1). The sudden increase in blood flow after re-
leasing the cuff causes an increase in endothelial shear stress and
endothelial NO production in the brachial artery which subsequently
dilates. Low brachial FMD is, therefore, used as a measure of en-
dothelial dysfunction.45 Studies have shown that patients with AF
have lower brachial FMD compared to patients in sinus rhythm.37,46
Moreover, this correlates with AF burden; persistent AF is associated
with lower brachial FMD than paroxysmal AF.47–49 In both the
Framingham heart study8 and multiethnic study,50 lower baseline
brachial FMD was predictive of new‐onset AF (Figure 3C). Moreover,
lower brachial FMD is associated with higher cardiovascular events in
patients with AF.51 One notable exception to these studies was the
Gutenberg health study, in which the relationship between low bra-
chial FMD and AF became nonsignificant after correction for con-
founding cardiovascular risk factors.52
Beyond the brachial artery, impaired vascular reactivity has also
been noted in the coronary circulation of patients with AF.53 Skalidis
et al.54 directly compared coronary flow reserve, the ratio of hy-
peremic to resting coronary blood flow, in the left atrial circumflex
artery branch of patients with lone AF and healthy con-
trols. While resting coronary blood flow was comparable between the
two groups, coronary flow reserve was significantly reduced in the
patients with AF during adenosine‐induced hyperemia.54 A similar
reduction in hyperemic coronary flow reserve was also noted in pa-
tients with AF using 15O‐H2O positron emission tomography (PET)
imaging9,55 (Figure 3D). Reduced coronary flow reserve assessed by
82rubidium PET imaging was independently associated with new‐
onset AF after adjustment for other cardiovascular risk factors.56 It is
important to note that endothelial dysfunction cannot be directly
inferred from these studies because they all use adenosine, an
endothelial‐independent vasodilator, to induce hyperemia. However,
Corban et al.57 used low‐dose acetylcholine, an endothelial‐
dependent vasodilator, to measure coronary flow reserve in patients
presenting with chest pain and nonobstructive coronary disease.
They demonstrated that impaired baseline coronary endothelial
function (defined as <50% increase in coronary blood flow in re-
sponse to acetylcholine) was an independent risk factor for in-
cident AF.57
3 | ENDOTHELIAL DYSFUNCTION—CAUSE
OR CONSEQUENCE OF AF?
While there is a strong consensus supporting the presence of en-
dothelial dysfunction in AF, significant controversy remains as to
whether it plays a contributory role in AF pathogenesis or alter-
natively occurs as a secondary consequence of AF (see Figure 2).
In support of the former, baseline endothelial dysfunction as
assessed by brachial FMD8,50 and coronary flow reserve57 has been
shown to precede and predict incident AF. Moreover, AF has well‐
established risk factors58 which are independently associated with
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endothelial dysfunction, namely aging,59 obesity,60 hypertension,61
diabetes,62 and ischemic heart disease.63 Endothelial dysfunction
may, therefore, act as the final common pathway linking these risk
factors to AF pathogenesis. However, the mechanisms linking en-
dothelial dysfunction to atrial arrhythmic substrate remain in-
completely understood. Left atrial endocardial cells to undergo an
endothelial–mesenchymal transition in AF and this may contribute
towards atrial fibrosis and extracellular remodeling.64 Endothelial
cells also regulate immune cell infiltration and inflammation within
the heart muscle. In a rat stroke model, Balint et al.65 demonstrated
that left atrial endothelial dysfunction was associated with increased
immune cell infiltration and fibrosis, particularly along the border
between the left atrium and pulmonary vein. Finally, endothelial
dysfunction is strongly associated with oxidative stress and the
overproduction of reactive oxygen species (ROS).66 ROS are known
to be arrhythmogenic by directly affecting cardiac ion currents (e.g.
L‐type Ca2+ current and late Na+ current) and Ca2+‐handling appa-
ratus (e.g., Ca2+/CaM‐dependent kinase II).67 ROS trigger focal
activity through early and delayed after depolarizations, promote
re‐entry through increasing action potential duration heterogeneity,
and promote myocardial fibrosis and loss of cardiomyocyte electrical
coupling.67
In contrast, others have proposed that endothelial dysfunction is
largely a secondary consequence of AF.68 Proponents argue that the
irregular heart rate, loss of synchronized atrial contraction, and
variable stroke volume reduce turbulence and endothelial shear
stress within the atria and blood vessels, thereby reducing the release
of endothelial NO and other vasoactive mediators.68 This view is
supported by studies that show endothelial function is restored fol-
lowing a return to sinus rhythm.69–77 These views are not mutually
exclusive and it is conceivable that endothelial dysfunction both
promotes and maintains AF. On the basis of this model, a positive
feedback loop exists in which endothelial dysfunction promotes atrial
arrhythmic substrate, thereby increasing the risk of AF which, in turn,
drives further endothelial dysfunction.
4 | ENDOTHELIAL DYSFUNCTION
AND THROMBOEMBOLISM
AF causes thromboembolism and stroke by impacting Virchow's triad
of blood stasis, hypercoagulability, and vessel wall abnormalities.78
Endothelial dysfunction has been shown to impact all three aspects
to promote clot formation (see Figure 2).
First, as previously described, endothelial dysfunction promotes
atrial arrhythmic substrate and increases the risk of incident AF. This
in turn causes a loss of atrial contraction resulting in static blood flow
and clot formation within the left atrial appendage. Fujii et al.79 de-
monstrated that endothelial dysfunction, as assessed by reduced
reactive hyperemia peripheral arterial tonometry (RH‐PAT) index
(Figure 3B), was independently associated with static atrial blood
flow, as determined by spontaneous echo contrast on transoeso-
phageal echocardiography.79
In addition, AF is strongly associated with a procoagulant state;
increased levels of clotting factors (factor VIII, fibrinogen), markers of
platelet activation (platelet factor 4, β‐thrombomodulin, P‐selectin),
and markers of fibrinolysis (D‐dimer, tissue plasminogen activator,
plasminogen activator inhibitor‐1) have all been described.78 En-
dothelial dysfunction induces the release of procoagulant factors
(VWF, tissue factor) and reduces the secretion of antithrombotic
factors (NO), thereby augmenting this procoagulant state.78 Inter-
estingly, Lim et al.80 demonstrated that in patients undergoing AF
ablation, both AF induction and rapid atrial pacing were sufficient to
cause an increase in the procoagulant molecules P‐selectin and
thrombin‐antithrombin complex after just 15 min. However, only AF
induction caused an increase in ADMA levels suggestive of en-
dothelial dysfunction.80 This study supports the view that a procoa-
gulant state can occur very rapidly following AF induction and that
endothelial dysfunction is related to the AF rhythm rather than rapid
heart rates.
Finally, endothelial dysfunction affects the atrial endocardium to
create a prothrombotic surface (Figure 2C). As previously discussed,
endothelial dysfunction is associated with major atrial endocardial
histological changes, including microscopic mural thrombi, desqua-
mation, and subendothelial edema and fibrosis.4,5,43
Noninvasive measures of endothelial function have shown pro-
mise as a predictor of adverse outcomes in AF. Raised VWF levels are
a predictor of MACEs and all‐cause mortality18 but not stroke.19,20
Raised ADMA levels positively correlate with the CHA2DS2‐VASc
score29,33 and are strongly associated with increased stroke and
mortality in AF.33 Lower brachial FMD levels are strongly associated
with adverse cardiovascular events, including stroke.51 In a non‐AF
cohort, a low RH‐PAT index significantly increased the risk of ischemic
stroke and improved discrimination of stroke risk by CHA2DS2‐VASc
score.81 Assessment of endothelial function may, therefore, play an
increasingly important role in AF risk stratification in the future.
5 | DOES AF TREATMENT AFFECT
ENDOTHELIAL FUNCTION?
There is strong evidence that restoration of sinus rhythm in AF im-
proves endothelial function. Following electrical cardioversion of AF,
studies have shown improvement in endothelial function biomarkers
(decreased VWF levels75,77 and increased plasma NOx levels75),
brachial FMD,72 and hyperemic forearm blood flow induced by
acetylcholine70 or exercise.71 Similarly, an increase in RH‐PAT index
is seen up to 6 months following AF catheter ablation.69 Interestingly,
Okawa et al.74 noted that catheter ablation of persistent, but not
paroxysmal AF, was associated with improvements in the RH‐PAT
index. Endothelial dysfunction also predicts AF recurrence following
ablation. Elevated biomarkers of endothelial dysfunction (increased
ADMA levels76), low baseline brachial FMD,73 and low RH‐PAT in-
dex82 have all been shown to predict AF recurrence. It is unclear
whether antiarrhythmic therapy or rate control drugs are also asso-
ciated with improvements in endothelial function.
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6 | ENDOTHELIAL DYSFUNCTION—A
PROMISING NEW THERAPEUTIC
PARADIGM?
Although contemporary AF pharmacotherapy relies on rate and/or
rhythm control drugs, there is a growing interest in targeting upstream
pathways and cardiovascular comorbidity to modify the underlying
processes of atrial remodeling and arrhythmic substrate. Although
these approaches have largely focussed on targeting atrial fibrosis and
inflammation, there is emerging evidence that endothelial dysfunction
is a promising new addition to this list. Angiotensin‐converting enzyme
inhibitors (ACE inhibitors)/angiotensin receptor blockers (ARBs),83
mineralocorticoid receptor antagonists (MRAs),84 and antioxidants
(such as N‐acetylcysteine and ascorbic acid)85 have all been shown to
reduce the risk of new‐onset AF and AF recurrence in large meta‐
analyses. Statins reduce all‐cause and cardiovascular mortality in AF,86
despite no consistent reduction in AF burden or recurrence.87 Al-
though these drugs have a multitude of physiological effects, they
have all been shown to improve endothelial function.88 Further studies
are required to develop and evaluate the effectiveness of drugs that
specifically target endothelial function. Phosphodiesterase‐5 (PDE‐5)
inhibitors improve endothelial function by augmenting cyclic guano-
sine monophosphate‐mediated vasodilatation and upregulating eNOS
expression.88 PDE‐5 inhibition has been shown to improve contractile
performance and exercise capacity in heart failure with reduced
ejection fraction89 and protect against ventricular arrhythmias in ani-
mal models of ischemia–reperfusion injury.90 Although in its early
preclinical stage of development, the eNOS transcription enhancer
AVE3085 has been shown to restore endothelial function in rat hy-
pertensive91 and heart failure models.92 These drugs remain to be
investigated in preclinical and clinical studies of AF. It is important to
note that endothelial dysfunction is more advanced in persistent and
permanent AF compared to paroxysmal AF, and, therefore, treatments
aimed at restoring endothelial function may have variable efficacy in
these different patient groups.
7 | CONCLUSION
Although progress has been made in understanding the role of en-
dothelial function in AF, significant questions remain unanswered.
Several mechanisms coupling endothelial dysfunction to the atrial
arrhythmic substrate have been proposed (endothelial–mesenchymal
transition and fibrosis, immune cell infiltration and inflammation, and
the generation of proarrhythmic ROS) but their effects on the elec-
trophysiological properties of the heart and AF initiation and main-
tenance remain poorly understood. Noninvasive assessment of
endothelial function has been shown to identify patients at high risk
of adverse outcome and AF recurrence, but it remains unclear
whether these patients benefit from more aggressive treatment of
cardiovascular risk factors. Finally, endothelial dysfunction represents
a promising upstream target for AF drug therapy. Although several
classes of drugs have shown promising results (ACE inhibitors/ARBs,
MRAs, antioxidants, and statins), further studies are required to
identify and test drugs that specifically target endothelial function.
ACKNOWLEDGMENT








1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dys-
function: testing and clinical relevance. Circulation. 2007;115(10):
1285‐1295.
2. Smiljic S. The clinical significance of endocardial endothelial dys-
function. Medicina (Kaunas). 2017;53(5):295‐302.
3. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular en-
dothelium and human diseases. Int J Biol Sci. 2013;9(10):
1057‐1069.
4. Sonoda Y, Teshima Y, Abe I, et al. Macrophage infiltration into the
endothelium of atrial tissue in atrial fibrillation. Circ J. 2017;81(11):
1742‐1744.
5. Masawa N, Yoshida Y, Yamada T, Joshita T, Ooneda G. Diagnosis of
cardiac thrombosis in patients with atrial fibrillation in the absence
of macroscopically visible thrombi. Virchows Arch A Pathol Anat
Histopathol. 1993;422(1):67‐71.
6. Ghiadoni L, Salvetti M, Muiesan ML, Taddei S. Evaluation of en-
dothelial function by flow mediated dilation: methodological issues
and clinical importance. High Blood Press Cardiovasc Prev. 2015;
22(1):17‐22.
7. Rosenberry R, Nelson MD. Reactive hyperemia: a review of meth-
ods, mechanisms, and considerations. Am J Physiol Regul Integr Comp
Physiol. 2020;318(3):R605‐R618.
8. Shaikh AY, Wang N, Yin X, et al. Relations of arterial stiffness and
brachial flow‐mediated dilation with new‐onset atrial fibrillation: the
Framingham heart study. Hypertension. 2016;68(3):590‐596.
9. Range FT, Schäfers M, Acil T, et al. Impaired myocardial perfusion
and perfusion reserve associated with increased coronary resistance
in persistent idiopathic atrial fibrillation. Eur Heart J. 2007;28(18):
2223‐2230.
10. Denis CV. Molecular and cellular biology of Von Willebrand factor.
Int J Hematol. 2002;75(1):3‐8.
11. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J.
Coagulation factors and the increased risk of stroke in nonvalvular
atrial fibrillation. Stroke. 1990;21(1):47‐51.
12. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of
thrombogenesis in chronic atrial fibrillation: effects of warfarin
treatment. Br Heart J. 1995;73(6):527‐533.
13. Conway DS, Heeringa J, Van Der Kuip DA, et al. Atrial fibrillation and
the prothrombotic state in the elderly: the Rotterdam study. Stroke.
2003;34(2):413‐417.
14. Freestone B, Gustafsson F, Chong AY, et al. Influence of atrial
fibrillation on plasma Von Willebrand factor, soluble E‐selectin, and
N‐terminal pro B‐type natriuretic peptide levels in systolic heart
failure. Chest. 2008;133(5):1203‐1208.
15. Mondillo S, Sabatini L, Agricola E, et al. Correlation between left
atrial size, prothrombotic state and markers of endothelial dys-
function in patients with lone chronic nonrheumatic atrial fibrillation.
Int J Cardiol. 2000;75(2):227‐232.
6 | BLACK ET AL.
16. Scridon A, Girerd N, Rugeri L, Nonin‐Babary E, Chevalier P. Pro-
gressive endothelial damage revealed by multilevel Von Willebrand
factor plasma concentrations in atrial fibrillation patients. Europace.
2013;15(11):1562‐1566.
17. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GY. Atrial
endocardial changes in mitral valve disease: a scanning electron
microscopy study. Am Heart J. 2000;140(5):777‐784.
18. Zhong C, Xin M, He L, Sun G, Shen F. Prognostic value of Von
Willebrand factor in patients with atrial fibrillation: a meta‐analysis.
Medicine. 2018;97(27):e11269.
19. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value
of plasma Von Willebrand factor and soluble P‐selectin as indices of
endothelial damage and platelet activation in 994 patients with
nonvalvular atrial fibrillation. Circulation. 2003;107(25):3141‐3145.
20. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma
von Willebrand factor levels to clinical factors for risk stratification
of patients with atrial fibrillation. Stroke. 2006;37(9):2294‐2300.
21. Ghimire K, Altmann HM, Straub AC, Isenberg JS. Nitric oxide: what's
new to NO? Am J Physiol Cell Physiol. 2017;312(3):C254‐C262.
22. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric
oxide synthase expression and nitric oxide production in atrial fi-
brillation: potential mechanisms for atrial thrombosis and stroke.
Circulation. 2002;106(22):2854‐2858.
23. Minamino T, Kitakaze M, Sato H, et al. Plasma levels of nitrite/
nitrate and platelet cGMP levels are decreased in patients with atrial
fibrillation. Arterioscler Thromb Vasc Biol. 1997;17(11):3191‐3195.
24. Han W, Fu S, Wei N, et al. Nitric oxide overproduction derived from
inducible nitric oxide synthase increases cardiomyocyte apoptosis in
human atrial fibrillation. Int J Cardiol. 2008;130(2):165‐173.
25. Chen H, Chu H, Shi Y, et al. Association between endothelial nitric
oxide synthase polymorphisms and atrial fibrillation: a meta‐analysis.
J Cardiovasc Transl Res. 2012;5(4):528‐534.
26. Vallance P, Leiper J. Cardiovascular biology of the asymmetric di-
methylarginine:dimethylarginine dimethylaminohydrolase pathway.
Arterioscler Thromb Vasc Biol. 2004;24(6):1023‐1030.
27. Cengel A, Sahinarslan A, Biberoğlu G, et al. Asymmetrical dimethy-
larginine level in atrial fibrillation. Acta Cardiol. 2008;63(1):33‐37.
28. Goette A, Hammwöhner M, Bukowska A, et al. The impact of rapid
atrial pacing on ADMA and endothelial NOS. Int J Cardiol. 2012;
154(2):141‐146.
29. Lao MC, Liu LJ, Luo CF, et al. Effect of asymmetrical dimethylargi-
nine for predicting pro‐thrombotic risk in atrial fibrillation. Zhonghua
Yi Xue Za Zhi. 2016;96(26):2059‐2063.
30. Ramuschkat M, Appelbaum S, Atzler D, et al. ADMA, subclinical
changes and atrial fibrillation in the general population. Int J Cardiol.
2016;203:640‐646.
31. Xia W, Qu X, Yu Y, Zhang X, Feng W, Song Y. Asymmetric di-
methylarginine concentration and early recurrence of atrial fibrilla-
tion after electrical cardioversion. Pacing Clin Electrophysiol. 2008;
31(8):1036‐1040.
32. Yang L, Xiufen Q, Shuqin S, et al. Asymmetric dimethylarginine
concentration and recurrence of atrial tachyarrythmias after cathe-
ter ablation in patients with persistent atrial fibrillation. J Interv Card
Electrophysiol. 2011;32(2):147‐154.
33. Horowitz JD, De Caterina R, Heresztyn T, et al. Asymmetric and
symmetric dimethylarginine predict outcomes in patients with atrial
fibrillation: an ARISTOTLE substudy. J Am Coll Cardiol. 2018;72(7):
721‐733.
34. Schnabel RB, Maas R, Wang N, et al. Asymmetric dimethylarginine,
related arginine derivatives, and incident atrial fibrillation. Am Heart
J. 2016;176:100‐106.
35. Krieglstein CF, Granger DN. Adhesion molecules and their role in
vascular disease. Am J Hypertens. 2001;14(6 Pt 2):44S‐54S.
36. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble
E‐selectin, VonWillebrand factor, soluble thrombomodulin, and total
body nitrate/nitrite product as indices of endothelial damage/dys-
function in paroxysmal, persistent, and permanent atrial fibrillation.
Chest. 2007;132(4):1253‐1258.
37. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated
dilatation as evidence of endothelial dysfunction in chronic atrial
fibrillation: relationship to plasma Von Willebrand factor and soluble
E‐selectin levels. Thromb Res. 2008;122(1):85‐90.
38. Willeit K, Pechlaner R, Willeit P, et al. Association between vascular
cell adhesion molecule 1 and atrial fibrillation. JAMA Cardiol. 2017;
2(5):516‐523.
39. Schnabel RB, Larson MG, Yamamoto JF, et al. Relation of multiple
inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol.
2009;104(1):92‐96.
40. Nomura S, Shimizu M. Clinical significance of procoagulant micro-
particles. J Intensive Care. 2015;3(1):2.
41. Ederhy S, Di Angelantonio E, Mallat Z, et al. Levels of circulating
procoagulant microparticles in nonvalvular atrial fibrillation. Am
J Cardiol. 2007;100(6):989‐994.
42. Siwaponanan P, Keawvichit R, Udompunturak S, et al. Altered profile
of circulating microparticles in nonvalvular atrial fibrillation. Clin
Cardiol. 2019;42(4):425‐431.
43. Ivanova VF, Sotnikov AV, Melnikov MV, Karpov AV. Ultrastructural
changes in the endocardium and endocrine cardiomyocytes in the
wall of the left atrial appendage in patients with atrial fibrillation.
Arkh Patol. 2020;82(5):16‐24.
44. Kume O, Teshima Y, Abe I, et al. Role of atrial endothelial cells in the
development of atrial fibrosis and fibrillation in response to pressure
overload. Cardiovasc Pathol. 2017;27:18‐25.
45. Khan AA, Thomas GN, Lip GYH, Shantsila A. Endothelial function in
patients with atrial fibrillation. Ann Med. 2020;52(1–2):1‐11.
46. Polovina M, Potpara T, Giga V, Stepanovic J, Ostojic M. Impaired
endothelial function in lone atrial fibrillation. Vojnosanit Pregl. 2013;
70(10):908‐914.
47. Siasos G, Mazaris S, Zisimos K, et al. The impact of atrial fibrillation
on endothelial dysfunction. J Am Coll Cardiol. 2015;65(suppl 10):
A477.
48. Komatsu T, Kunugita F, Ozawa M, et al. Relationship between im-
pairment of the vascular endothelial function and the CHA2DS2‐
VASc score in patients with sinus rhythm and non‐valvular atrial
fibrillation. Intern Med. 2018;57(15):2131‐2139.
49. Mazaris S, Siasos G, Oikonomou E, et al. Abstract 11548: the role
of endothelial function and systemic inflammation on paroxysmal
and chronic atrial fibrillation. Circulation. 2018;138(Suppl 1):
A11548.
50. O'Neal WT, Efird JT, Yeboah J, et al. Brachial flow‐mediated dilation
and incident atrial fibrillation: the multi‐ethnic study of athero-
sclerosis. Arterioscler Thromb Vasc Biol. 2014;34(12):2717‐2720.
51. Perri L, Pastori D, Pignatelli P, Violi F, Loffredo L. Flow‐mediated
dilation is associated with cardiovascular events in non‐valvular at-
rial fibrillation patients. Int J Cardiol. 2015;179:139‐143.
52. Börschel CS, Rübsamen N, Ojeda FM, et al. Noninvasive peripheral
vascular function and atrial fibrillation in the general population.
J Hypertens. 2019;37(5):928‐934.
53. Kochiadakis GE, Kallergis EM. Impact of atrial fibrillation on coronary
blood flow: a systematic review. J Atr Fibrillation. 2012;5(3):458.
54. Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE,
Vardas PE. Isolated atrial microvascular dysfunction in patients with
lone recurrent atrial fibrillation. J Am Coll Cardiol. 2008;51(21):
2053‐2057.
55. Range FT, Paul M, Schäfers KP, et al. Myocardial perfusion in non-
ischemic dilated cardiomyopathy with and without atrial fibrillation.
J Nucl Med. 2009;50(3):390‐396.
56. Al‐Mallah MH, Ahmed A, Sulaiman IF, et al. Non‐invasive coronary
flow reserve predicts incident atrial fibrillation. J Am Coll Cardiol.
2017;69(suppl 11):1405.
BLACK ET AL. | 7
57. Corban MT, Godo S, Burczak DR, et al. Coronary endothelial dys-
function is associated with increased risk of incident atrial fibrilla-
tion. J Am Heart Assoc. 2020;9(8):e014850.
58. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts
incidence of atrial fibrillation in a racially and geographically diverse
population: the CHARGE‐AF consortium. J Am Heart Assoc. 2013;
2(2):e000102.
59. Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction
in the aging vasculature and role in age‐related disease. Circ Res.
2018;123(7):825‐848.
60. Avogaro A, de Kreutzenberg SV. Mechanisms of endothelial dys-
function in obesity. Clin Chim Acta. 2005;360(1‐2):9‐26.
61. Dharmashankar K, Widlansky ME. Vascular endothelial function and
hypertension: insights and directions. Curr Hypertens Rep. 2010;
12(6):448‐455.
62. Hamilton SJ, Watts GF. Endothelial dysfunction in diabetes: patho-
genesis, significance, and treatment. Rev Diabet Stud. 2013;10(2‐3):
133‐156.
63. Davignon J, Ganz P. Role of endothelial dysfunction in athero-
sclerosis. Circulation. 2004;109(23):III27‐III32.
64. Kato T, Sekiguchi A, Sagara K, et al. Endothelial‐mesenchymal
transition in human atrial fibrillation. J Cardiol. 2017;69(5):
706‐711.
65. Balint B, Jaremek V, Thorburn V, Whitehead SN, Sposato LA. Left
atrial microvascular endothelial dysfunction, myocardial inflamma-
tion and fibrosis after selective insular cortex ischemic stroke. Int
J Cardiol. 2019;292:148‐155.
66. Korantzopoulos P, Letsas K, Fragakis N, Tse G, Liu T. Oxidative
stress and atrial fibrillation: an update. Free Radic Res. 2018;52
(11‐12):1199‐1209.
67. Sovari AA. Cellular and molecular mechanisms of arrhythmia by
oxidative stress. Cardiol Res Pract. 2016;2016:9656078.
68. Guazzi M, Arena R. Endothelial dysfunction and pathophysiological
correlates in atrial fibrillation. Heart. 2009;95(2):102‐106.
69. Yoshino S, Yoshikawa A, Hamasaki S, et al. Atrial fibrillation‐induced
endothelial dysfunction improves after restoration of sinus rhythm.
Int J Cardiol. 2013;168(2):1280‐1285.
70. Takahashi N, Ishibashi Y, Shimada T, et al. Atrial fibrillation impairs
endothelial function of forearm vessels in humans. J Card Fail. 2001;
7(1):45‐54.
71. Takahashi N, Ishibashi Y, Shimada T, et al. Impaired exercise‐induced
vasodilatation in chronic atrial fibrillation—role of endothelium‐
derived nitric oxide. Circ J. 2002;66(6):583‐588.
72. Skalidis EI, Zacharis EA, Tsetis DK, et al. Endothelial cell function
during atrial fibrillation and after restoration of sinus rhythm. Am
J Cardiol. 2007;99(9):1258‐1262.
73. Shin SY, Na JO, Lim HE, et al. Improved endothelial function in
patients with atrial fibrillation through maintenance of sinus rhythm
by successful catheter ablation. J Cardiovasc Electrophysiol. 2011;
22(4):376‐382.
74. Okawa K, Miyoshi T, Tsukuda S, et al. Differences in endothelial
dysfunction induced by paroxysmal and persistent atrial fibrillation:
Insights from restoration of sinus rhythm by catheter ablation. Int
J Cardiol. 2017;244:180‐185.
75. Nikitovic D, Zacharis EA, Manios EG, et al. Plasma levels of nitrites/
nitrates in patients with chronic atrial fibrillation are increased after
electrical restoration of sinus rhythm. J Interv Card Electrophysiol.
2002;7(2):171‐176.
76. Lim HS, Willoughby SR, Schultz C, et al. Successful catheter ablation
decreases platelet activation and improves endothelial function in
patients with atrial fibrillation. Heart Rhythm. 2014;11(11):
1912‐1918.
77. Freestone B, Chong AY, Blann AD, Lip GY. The effects of direct
current cardioversion for persistent atrial fibrillation on indices of
endothelial damage/dysfunction. Thromb Res. 2006;118(4):
479‐485.
78. Ding WY, Gupta D, Lip GYH. Atrial fibrillation and the prothrombotic
state: revisiting Virchow's triad in 2020. Heart. 2020;106(19):
1463‐1468.
79. Fujii A, Inoue K, Nagai T, et al. Clinical significance of peripheral
endothelial function for left atrial blood stagnation in nonvalvular
atrial fibrillation patients with low‐to‐intermediate stroke risk. Circ J.
2016;80(10):2117‐2123.
80. Lim HS, Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on
atrial thrombogenesis in humans: impact of rate and rhythm. J Am
Coll Cardiol. 2013;61(8):852‐860.
81. Toya T, Sara JD, Ahmad A, et al. Incremental prognostic impact of
peripheral microvascular endothelial dysfunction on the develop-
ment of ischemic stroke. J Am Heart Assoc. 2020;9(9):e015703.
82. Kobayashi H, Okada A, Tabata H, et al. Association between reactive
hyperemia peripheral arterial tonometry index and atrial fibrillation
recurrence after catheter ablation. IJC Heart Vasculature. 2019;24:
100385.
83. Zhao D, Wang ZM, Wang LS. Prevention of atrial fibrillation with
renin‐angiotensin system inhibitors on essential hypertensive pa-
tients: a meta‐analysis of randomized controlled trials. J Biomed Res.
2015;29(6):475‐485.
84. Alexandre J, Dolladille C, Douesnel L, et al. Effects of miner-
alocorticoid receptor antagonists on atrial fibrillation occurrence: a
systematic review, meta‐analysis, and meta‐regression to identify
modifying factors. J Am Heart Assoc. 2019;8(22):e013267.
85. Violi F, Pastori D, Pignatelli P, Loffredo L. Antioxidants for preven-
tion of atrial fibrillation: a potentially useful future therapeutic ap-
proach? A review of the literature and meta‐analysis. Europace.
2014;16(8):1107‐1116.
86. Pastori D, Baratta F, Di Rocco A, et al. Statin use and mortality in
atrial fibrillation: a systematic review and meta‐analysis of 100,287
patients. Pharmacol Res. 2021;165:105418.
87. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial
fibrillation: collaborative meta‐analysis of published and unpublished
evidence from randomised controlled trials. BMJ. 2011;342:d1250.
88. Su JB. Vascular endothelial dysfunction and pharmacological treat-
ment. World J Cardiol. 2015;7(11):719‐741.
89. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with
sildenafil improves left ventricular diastolic function, cardiac geo-
metry, and clinical status in patients with stable systolic heart failure:
results of a 1‐year, prospective, randomized, placebo‐controlled
study. Circ Heart Fail. 2011;4(1):8‐17.
90. Nagy O, Hajnal A, Parratt JR, Vegh A. Sildenafil (Viagra) reduces
arrhythmia severity during ischaemia 24 h after oral administration
in dogs. Br J Pharmacol. 2004;141(4):549‐551.
91. Yang Q, Xue HM, Wong WT, et al. AVE3085, an enhancer of en-
dothelial nitric oxide synthase, restores endothelial function and
reduces blood pressure in spontaneously hypertensive rats. Br
J Pharmacol. 2011;163(5):1078‐1085.
92. Schafer A, Fraccarollo D, Widder J, Eigenthaler M, Ertl G,
Bauersachs J. Inhibition of platelet activation in rats with severe
congestive heart failure by a novel endothelial nitric oxide synthase
transcription enhancer. Eur J Heart Fail. 2009;11(4):336‐341.
How to cite this article: Black N, Mohammad F, Saraf K,
Morris G. Endothelial function and atrial fibrillation: A missing
piece of the puzzle? J Cardiovasc Electrophysiol. 2021;1‐8.
doi:10.1111/jce.15277
8 | BLACK ET AL.
